SecBot SecBot
8-K ·Filed Jul 30, 2026

REPL

Replimune Group, Inc.
BULLISH
Impact 7/10
Horizonimmediate Processed3mo ago SEC0001104659-26-088481
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

The advisory committee vote today is the key catalyst. A positive vote would likely lead to accelerated approval and significant stock upside; a negative vote would be a major setback. Monitor the vote outcome and FDA decision timeline.

DirectionBullish
Confidencemedium
Horizonimmediate

TUDRIQEV

● Neutral Named in this 8-K
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already approved and commercially available in the U.S. since October 2026.
Next catalyst
None dated

What to watchTUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$5.41
T+0 close · Jul 30, 2026 · via day close
Latest settled
+111.83%
T+60 · $11.46
Vs SPY
+109.37%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $5.41entry
  2. T+1 · 4mo ago +107.02%α +106.32% · $11.20
  3. T+5 · 3mo ago +137.71%α +134.09% · $12.86
  4. T+20 · 3mo ago +188.35%α +184.39% · $15.60
  5. T+60 · 25d ago +111.83%α +109.37% · $11.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Replimune presented its BLA resubmission for RP1 (vusolimogene oderparepvec, TUDRIQEV) in combination with nivolumab to the FDA advisory committee for advanced melanoma. The IGNYTE Phase 2 data showed a 33.6% ORR (16.4% CR), median DOR of 24.8 months, and a 3-year OS rate of 47.8% with a manageable safety profile. The FDA's initial clinical review had already recommended accelerated approval, making today's advisory committee vote a pivotal catalyst for the stock.

Key Facts

  • IGNYTE Phase 2 ORR: 33.6% (95% CI: 25.8, 42) with 16.4% complete response rate
  • Median duration of response: 24.8 months (95% CI: 14.8, NE)
  • 3-year overall survival rate: 47.8% (median OS 32.9 months)
  • No treatment-related Grade 5 adverse events; mainly Grade 1-2 toxicities
  • FDA clinical review (July 2025) recommended accelerated approval, citing substantial evidence of effectiveness
  • Advisory committee meeting held July 30, 2026; outcome will influence FDA decision

Financial Impact

No financial data in filing; potential approval would be transformative for pre-revenue biotech with $454M market cap

Risk Factors

  • Advisory committee may vote against approval despite positive FDA review
  • FDA is not bound by committee vote and could still reject
  • Confirmatory trial (IGNYTE-3) OS data not expected until 2030, leaving accelerated approval subject to post-market verification

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
57% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-088481
Document: tm2621663d1_8k.htm0001104659-26-088481
Document: 0001104659-26-088481-index-headers.html0001104659-26-088481
Document: 0001104659-26-088481-index.html0001104659-26-088481
Document: 0001104659-26-088481.txt0001104659-26-088481

Track record

32 reports on REPL

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +75.56% at T+60 after the May 30, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
  2. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
  5. Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
  6. Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
  7. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
  8. Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
  9. Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
  10. Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
Showing 10 of 32

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026